Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 20Male Breast Health StudiesBreast Cancer Treatment StudiesEstrogen and related hormone effects

The DOI matches its Crossref record; its reference list is not available.

Pharmacologic treatment of male breast cancer

Hayes, Teresa G·2009·Expert Opinion on Pharmacotherapy
DOI 10.1517/14656560903200634
Open this paper in CoChat — free account

Abstract

Male breast cancer is an uncommon condition. It often occurs in settings in which there is an imbalance between androgens and oestrogens. Genetics plays an important role, as many cases are associated with mutations in BRCA2 or other genes. Male breast cancer occurs at an older age than female breast cancer and is frequently diagnosed at a later stage. Tumors are predominantly oestrogen and progesterone positive. Prognosis is approximately equivalent to that of breast cancer in females when matched for age, stage and hormonal receptors. The recommended treatment for male breast cancer is similar to that for breast cancer in postmenopausal females. However, the presence of androgens in males has a strong effect on the hormonal milieu and the ability of male patients to respond to hormonal agents. When pharmacologic treatment is required, tamoxifen is effective for first-line therapy. Other hormonal approaches such as orchiectomy, aromatase inhibitors and androgen ablation may be useful in later lines of therapy.

Overview

Integrity signals

Registry

Crossref · 10.1517/14656560903200634

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 200 · Cited by 20

Research works printed but not linked: 184

  1. Jemal, 2009, CA Cancer J Clin, 59, 225, 10.3322/caac.20006 · DOI · Paper page
  2. Csokay, 1999, Cancer Res, 59, 995
  3. El-Gazayerli, 1963, Br J Cancer, 17, 566, 10.1038/bjc.1963.75 · DOI
  4. Bhagwandeen, 1972, East Afr Med J, 49, 89
  5. Ojara, 1978, East Afr Med J, 55, 489
  6. Donegan, 1996, Surg Clin North Am, 76, 343, 10.1016/S0039-6109(05)70443-6 · DOI
  7. Ravandi-Kashani, 1998, Eur J Cancer, 34, 1341, 10.1016/S0959-8049(98)00028-8 · DOI
  8. Thomas, 1993, Epidemiol Rev, 15, 220, 10.1093/oxfordjournals.epirev.a036108 · DOI
  9. English, 2000, Int J Dermatol, 39, 881, 10.1046/j.1365-4362.2000.00007.x · DOI
  10. Nirmul, 1983, Br J Cancer, 48, 423, 10.1038/bjc.1983.208 · DOI
  11. Schlappack, 1986, Cancer Detect Prev, 9, 319
  12. Pritchard, 1988, JAMA, 259, 2278, 10.1001/jama.1988.03720150054036 · DOI
  13. Ganly, 1995, Br J Surg, 82, 341, 10.1002/bjs.1800820319 · DOI
  14. Symmers, 1968, Br Med J, 2, 83, 10.1136/bmj.2.5597.83 · DOI
  15. Medras, 2006, Breast Cancer Res Treat, 96, 263, 10.1007/s10549-005-9074-y · DOI
  16. 10.1093/jnci/djh062 · DOI
  17. Hirose, 2007, World J Surg Oncol, 5, 60, 10.1186/1477-7819-5-60 · DOI
  18. Jackson, 1965, Br Med J, 1, 223, 10.1136/bmj.1.5429.223 · DOI
  19. Scheike, 1973, Acta Pathol Microbiol Scand [A], 81, 352
  20. Hultborn, 1997, Anticancer Res, 17, 4293
  21. Harnden, 1971, J Med Genet, 8, 460, 10.1136/jmg.8.4.460 · DOI
  22. Fentiman, 2006, Lancet, 367, 595, 10.1016/S0140-6736(06)68226-3 · DOI
  23. Thorlacius, 1995, Lancet, 346, 544, 10.1016/S0140-6736(95)91383-1 · DOI
  24. Couch, 1996, Nat Genet, 13, 123, 10.1038/ng0596-123 · DOI
  25. Haraldsson, 1998, Cancer Res, 58, 1367
  26. Syrjakoski, 2004, Neoplasia, 6, 541, 10.1593/neo.04193 · DOI
  27. Friedman, 1997, Am J Hum Genet, 60, 313
  28. Frank, 2002, J Clin Oncol, 20, 1480, 10.1200/JCO.20.6.1480 · DOI
  29. Basham, 2002, Breast Cancer Res, 4, R2, 10.1186/bcr419 · DOI
  30. Fackenthal, 2001, J Med Genet, 38, 159, 10.1136/jmg.38.3.159 · DOI
  31. Wasielewski, 2009, Breast Cancer Res Treat, 116, 397, 10.1007/s10549-008-0162-7 · DOI
  32. Syrjakoski, 2004, Int J Cancer, 108, 475, 10.1002/ijc.11384 · DOI
  33. Ohayon, 2004, Int J Cancer, 108, 479, 10.1002/ijc.11603 · DOI
  34. Griffin JF, Wilson JD. Disorders of the testes. In: Isselbacher KJ, editor, Harrison's Principles of Internal Medicine. 13th edition. New York: Mc-Graw-Hill, Inc. 1994. p. 2006-17
  35. Orth DN, Kovacs WJ. The adrenal cortex. In: Wilson JD, editor, Williams Textbook of Endocrinology. 9th edition. Philadelphia: W.B.Saunders Company; 1998. p. 517-664
  36. Bhasin S, Jameson JL. Disorders of the testes and male reproductive system In: Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL, et al, editors, Harrison's Principles of Internal Medicine. 17th edition. The McGraw-Hill Companies, Inc. 2008
  37. Simpson, 2000, J Mol Endocrinol, 25, 149, 10.1677/jme.0.0250149 · DOI
  38. Sasano, 1997, J Steroid Biochem Mol Biol, 61, 293, 10.1016/S0960-0760(97)80026-X · DOI
  39. Dakin Hachè, 2007, Breast Cancer Res Treat, 105, 169, 10.1007/s10549-006-9448-9 · DOI
  40. Hamilton, 2001, Oncology (Williston Park), 15, 965
  41. Rayson, 1998, Cancer, 83, 1947, 10.1002/(SICI)1097-0142(19981101)83:9<1947::AID-CNCR10>3.0.CO;2-J · DOI
  42. Ruff, 1981, J Surg Oncol, 18, 55, 10.1002/jso.2930180109 · DOI
  43. Nomura, 1977, Gann, 68, 333
  44. Everson, 1980, Cancer Res, 40, 991
  45. Gupta, 1980, Cancer, 46, 1781, 10.1002/1097-0142(19801015)46:8<1781::AID-CNCR2820460814>3.0.CO;2-F · DOI
  46. Mercer, 1984, Aust N Z J Surg, 54, 215, 10.1111/j.1445-2197.1984.tb05305.x · DOI
  47. Morimoto, 1990, J Surg Oncol, 44, 180, 10.1002/jso.2930440311 · DOI
  48. Davis, 1992, J Am Osteopath Assoc, 92, 1005, 10.7556/jaoa.1992.92.8.1005 · DOI
  49. Cutuli, 1995, Eur J Cancer, 31, 1960, 10.1016/0959-8049(95)00366-5 · DOI
  50. Williams, 1996, J Natl Med Assoc, 88, 439
  51. Munoz de Toro, 1998, J Steroid Biochem Mol Biol, 67, 333, 10.1016/S0960-0760(98)00124-1 · DOI
  52. Pich, 1999, Br J Cancer, 79, 959, 10.1038/sj.bjc.6690153 · DOI
  53. Meijer-van Gelder, 2001, Breast Cancer Res Treat, 68, 249, 10.1023/A:1012221921416 · DOI
  54. Weber-Chappuis, 1996, Eur J Cancer, 32, 1686, 10.1016/0959-8049(96)00154-2 · DOI
  55. Donegan, 1998, Cancer, 83, 498, 10.1002/(SICI)1097-0142(19980801)83:3<498::AID-CNCR19>3.0.CO;2-R · DOI
  56. Calandra, 1984, Prog Clin Biol Res, 142, 97
  57. Kidwai, 2004, Breast Cancer Res, 6, R18, 10.1186/bcr733 · DOI
  58. Giordano, 2004, Cancer, 101, 51, 10.1002/cncr.20312 · DOI
  59. Anderson, 2001, Proc Annu Meet Am Soc Clin Oncol, 20, A1691
  60. Romain, 1995, Eur J Cancer, 31, 411, 10.1016/0959-8049(94)00496-R · DOI
  61. El-Tamer, 2000, Breast Cancer Res Treat, 64, 128
  62. Bloom, 2001, Am J Surg, 182, 389, 10.1016/S0002-9610(01)00733-4 · DOI
  63. Barlund, 2004, Int J Cancer, 111, 968, 10.1002/ijc.20307 · DOI
  64. Giordano, 2002, Ann Intern Med, 137, 678, 10.7326/0003-4819-137-8-200210150-00013 · DOI
  65. Joshi, 1996, Cancer, 77, 490, 10.1002/(SICI)1097-0142(19960201)77:3<490::AID-CNCR10>3.0.CO;2-# · DOI
  66. Shpitz, 2000, J Surg Oncol, 75, 252, 10.1002/1096-9098(200012)75:4<252::AID-JSO5>3.0.CO;2-2 · DOI
  67. Bines, 1997, Proc Annu Meet Am Soc Clin Oncol, 16, A558
  68. Rudlowski, 2004, Breast Cancer Res Treat, 84, 215, 10.1023/B:BREA.0000019953.92921.7e · DOI
  69. Avisar, 2006, Clin Breast Cancer, 7, 331, 10.3816/CBC.2006.n.046 · DOI
  70. Rudlowski, 2006, Int J Cancer, 118, 2455, 10.1002/ijc.21646 · DOI
  71. Andre, 2007, Pathobiology, 74, 323, 10.1159/000110025 · DOI
  72. Shak, 2009, J Clin Oncol, 27, 10.1200/jco.2009.27.15_suppl.549 · DOI
  73. Giordano, 2002, Am J Clin Oncol, 25, 235, 10.1097/00000421-200206000-00006 · DOI
  74. Golshan, 2007, Breast, 16, 653, 10.1016/j.breast.2007.05.012 · DOI
  75. Herrmann, 1951, Ann Surg, 133, 191, 10.1097/00000658-195102000-00006 · DOI
  76. Hultborn, 1987, Acta Oncol, 26, 327, 10.3109/02841868709104357 · DOI
  77. Kraybill, 1981, Cancer, 47, 2185, 10.1002/1097-0142(19810501)47:9<2185::AID-CNCR2820470913>3.0.CO;2-B · DOI
  78. Neifeld, 1976, Cancer, 37, 992, 10.1002/1097-0142(197602)37:2<992::AID-CNCR2820370257>3.0.CO;2-B · DOI
  79. Treves, 1959, Cancer, 12, 820, 10.1002/1097-0142(195907/08)12:4<820::AID-CNCR2820120427>3.0.CO;2-9 · DOI
  80. Kantarjian, 1983, Arch Intern Med, 143, 237, 10.1001/archinte.1983.00350020055012 · DOI
  81. Labrie, 1990, Clin Invest Med, 13, 275
  82. Borgen, 1991, Semin Surg Oncol, 7, 314, 10.1002/ssu.2980070516 · DOI
  83. Doberauer, 1988, Cancer, 62, 474, 10.1002/1097-0142(19880801)62:3<474::AID-CNCR2820620305>3.0.CO;2-2 · DOI
  84. Lopez, 1982, Cancer, 49, 9, 10.1002/1097-0142(19820101)49:1<9::AID-CNCR2820490103>3.0.CO;2-# · DOI
  85. Vorobiof, 1987, Cancer, 59, 688, 10.1002/1097-0142(19870215)59:4<688::AID-CNCR2820590404>3.0.CO;2-E · DOI
  86. Kennedy, 1972, Cancer, 29, 1606, 10.1002/1097-0142(197206)29:6<1606::AID-CNCR2820290627>3.0.CO;2-# · DOI
  87. Lopez, 1985, Oncology, 42, 345, 10.1159/000226061 · DOI
  88. Harris, 1986, Br J Cancer, 54, 657, 10.1038/bjc.1986.223 · DOI
  89. Feldman, 1986, Ann Intern Med, 104, 123, 10.7326/0003-4819-104-1-123_2 · DOI
  90. Li, 1970, Cancer, 25, 678, 10.1002/1097-0142(197003)25:3<678::AID-CNCR2820250326>3.0.CO;2-N · DOI
  91. Jaiyesimi, 1992, Ann Intern Med, 117, 771, 10.7326/0003-4819-117-9-771 · DOI
  92. Patel, 1984, Cancer, 53, 1344, 10.1002/1097-0142(19840315)53:6<1344::AID-CNCR2820530621>3.0.CO;2-Q · DOI
  93. Ribeiro, 1976, Br J Cancer, 33, 465, 10.1038/bjc.1976.72 · DOI
  94. Pannuti, 1982, Cancer Treat Rep, 66, 1763
  95. Mitsuyasu, 1981, Arch Intern Med, 141, 809, 10.1001/archinte.1981.00340060117031 · DOI
  96. Becher, 1981, N Engl J Med, 305, 169
  97. Abele, 1981, N Engl J Med, 305, 1091, 10.1056/NEJM198110293051815 · DOI
  98. Patterson, 1980, Cancer Treat Rep, 64, 801
  99. Comet, 2009, Bull Cancer, 96, 181, 10.1684/bdc.2008.0813 · DOI
  100. Crichlow, 1990, Surg Clin North Am, 70, 1165, 10.1016/S0039-6109(16)45237-0 · DOI
  101. Dimitrov, 2007, Oncologist, 12, 798, 10.1634/theoncologist.12-7-798 · DOI
  102. Hortobagyi, 1979, Cancer Treat Rep, 63, 539
  103. Cantwell, 1978, Lancet, 2, 582, 10.1016/S0140-6736(78)92925-2 · DOI
  104. Aisner, 1979, Arch Intern Med, 139, 480, 10.1001/archinte.1979.03630410084025 · DOI
  105. Hilliard, 1984, J Surg Oncol, 25, 42, 10.1002/jso.2930250112 · DOI
  106. Tateishi, 1992, J Surg Oncol, 51, 71, 10.1002/jso.2930510118 · DOI
  107. van Rijswijk, 1997, Eur J Cancer, 33, 2282, 10.1016/S0959-8049(97)00258-X · DOI
  108. Kanoh, 2000, Breast Cancer, 7, 256, 10.1007/BF02967470 · DOI
  109. Ribeiro, 1992, Br J Cancer, 65, 252, 10.1038/bjc.1992.50 · DOI
  110. Anelli, 1994, Cancer, 74, 74, 10.1002/1097-0142(19940701)74:1<74::AID-CNCR2820740113>3.0.CO;2-# · DOI
  111. Visram, 2009, J Clin Oncol, 27, 10.1200/jco.2009.27.15_suppl.e11613 · DOI
  112. Takei, 2001, Surg Today, 31, 149, 10.1007/s005950170199 · DOI
  113. Agrawal, 2007, Breast Cancer Res Treat, 101, 123, 10.1007/s10549-006-9266-0 · DOI
  114. Nabholtz, 2000, J Clin Oncol, 18, 3758, 10.1200/JCO.2000.18.22.3758 · DOI
  115. Bonneterre, 2000, J Clin Oncol, 18, 3748, 10.1200/JCO.2000.18.22.3748 · DOI
  116. Howell, 2005, Lancet, 365, 60, 10.1016/S0140-6736(05)74803-0 · DOI
  117. Arriola, 2007, Clin Transl Oncol, 9, 192, 10.1007/s12094-007-0034-3 · DOI
  118. Pant, 2008, Med Oncol, 25, 294, 10.1007/s12032-007-9034-y · DOI
  119. Brueggemeier, 2005, Endocr Rev, 26, 331, 10.1210/er.2004-0015 · DOI
  120. Geisler, 1996, Br J Cancer, 74, 1286, 10.1038/bjc.1996.531 · DOI
  121. Lonning, 1998, Breast Cancer Res Treat, 49, S53, 10.1023/A:1006000806630 · DOI
  122. Mauras, 2000, J Clin Endocrinol Metab, 85, 2370
  123. Nordman, 2008, Breast J, 14, 562, 10.1111/j.1524-4741.2008.00648.x · DOI
  124. Nahleh, 2006, Cancer Treat Rev, 32, 101, 10.1016/j.ctrv.2005.12.007 · DOI
  125. Ellinwood, 1984, J Clin Endocrinol Metab, 59, 1088, 10.1210/jcem-59-6-1088 · DOI
  126. Shetty, 1998, Steroids, 63, 414, 10.1016/S0039-128X(98)00042-7 · DOI
  127. Dukes, 1996, J Steroid Biochem Mol Biol, 58, 439, 10.1016/0960-0760(96)00064-7 · DOI
  128. Turner, 2000, J Endocrinol, 164, 225, 10.1677/joe.0.1640225 · DOI
  129. Knoche, 1999, Breast J, 5, 176, 10.1046/j.1524-4741.1999.98055.x · DOI
  130. Zabolotny, 2005, J Surg Oncol, 90, 26, 10.1002/jso.20233 · DOI
  131. Italiano, 2004, Rev Med Interne, 25, 323, 10.1016/j.revmed.2003.12.006 · DOI
  132. Soon Wong, 2007, J Clin Oncol, 25, 3787, 10.1200/JCO.2007.13.0583 · DOI
  133. Giordano, 2006, J Clin Oncol, 24, e42, 10.1200/JCO.2006.07.2397 · DOI
  134. Doyen, 2009, J Clin Oncol, 27, 10.1200/jco.2009.27.15_suppl.1130 · DOI
  135. Stewart, 2006, N Engl J Med, 355, 1724, 10.1056/NEJMe068189 · DOI
  136. Horn, 1976, Oncology, 33, 188, 10.1159/000225140 · DOI
  137. Yap, 1980, JAMA, 243, 1739, 10.1001/jama.1980.03300430041021 · DOI
  138. Rivera, 2000, Cancer, 89, 2195, 10.1002/1097-0142(20001201)89:11<2195::AID-CNCR7>3.0.CO;2-W · DOI · Paper page
  139. Alexandre, 2000, J Clin Oncol, 18, 562, 10.1200/JCO.2000.18.3.562 · DOI
  140. Lopez, 1985, Oncology, 42, 205, 10.1159/000226032 · DOI
  141. Tranum, 1982, Cancer, 49, 835, 10.1002/1097-0142(19820301)49:5<835::AID-CNCR2820490502>3.0.CO;2-Z · DOI
  142. Misset, 1999, Ann Oncol, 10, 553, 10.1023/A:1026418831238 · DOI
  143. Buzdar, 1989, Am J Clin Oncol, 12, 123, 10.1097/00000421-198904000-00007 · DOI
  144. Tormey, 1982, Cancer, 50, 1235, 10.1002/1097-0142(19821001)50:7<1235::AID-CNCR2820500703>3.0.CO;2-L · DOI
  145. Jassem, 2001, J Clin Oncol, 19, 1707, 10.1200/JCO.2001.19.6.1707 · DOI
  146. Sandler, 1994, Am Surg, 60, 816
  147. Rudlowski, 2001, N Engl J Med, 345, 997
  148. Hayashi, 2009, Breast Cancer, 16, 136, 10.1007/s12282-008-0060-1 · DOI
  149. Carmona-Bayonas, 2007, Breast, 16, 323, 10.1016/j.breast.2006.12.010 · DOI
  150. 1998, Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4 · DOI
  151. Goss, 1999, Cancer, 85, 629, 10.1002/(SICI)1097-0142(19990201)85:3<629::AID-CNCR13>3.0.CO;2-V · DOI
  152. Giordano, 2005, Cancer, 104, 2359, 10.1002/cncr.21526 · DOI
  153. Vinod, 1999, Australas Radiol, 43, 69, 10.1046/j.1440-1673.1999.00601.x · DOI
  154. Yildirim, 1998, Eur J Surg Oncol, 24, 548, 10.1016/S0748-7983(98)93608-3 · DOI
  155. Margaria, 2000, Oncol Rep, 7, 1035
  156. Patel, 1989, Cancer, 64, 1583, 10.1002/1097-0142(19891015)64:8<1583::AID-CNCR2820640804>3.0.CO;2-Q · DOI
  157. Bagley, 1987, Am J Clin Oncol, 10, 55, 10.1097/00000421-198702000-00013 · DOI
  158. Walshe, 2007, Breast Cancer Res Treat, 103, 177, 10.1007/s10549-006-9363-0 · DOI
  159. Ragaz, 1997, N Engl J Med, 337, 956, 10.1056/NEJM199710023371402 · DOI
  160. Overgaard, 1997, N Engl J Med, 337, 949, 10.1056/NEJM199710023371401 · DOI
  161. Fowble, 1988, J Clin Oncol, 6, 1107, 10.1200/JCO.1988.6.7.1107 · DOI
  162. Heller, 1978, Ann Surg, 188, 60, 10.1097/00000658-197807000-00010 · DOI
  163. Ciatto, 1990, Tumori, 76, 555, 10.1177/030089169007600608 · DOI
  164. Salvadori, 1994, Eur J Cancer, 30, 930, 10.1016/0959-8049(94)90117-1 · DOI
  165. Rudan, 1997, Acta Med Croatica, 51, 135
  166. Nahleh, 2007, Cancer, 109, 1471, 10.1002/cncr.22589 · DOI
  167. Langlands, 1976, Clin Radiol, 27, 21, 10.1016/S0009-9260(76)80008-6 · DOI
  168. Erlichman, 1984, J Clin Oncol, 2, 903, 10.1200/JCO.1984.2.8.903 · DOI
  169. Guinee, 1993, Cancer, 71, 154, 10.1002/1097-0142(19930101)71:1<154::AID-CNCR2820710125>3.0.CO;2-# · DOI
  170. Willsher, 1997, Am J Surg, 173, 185, 10.1016/S0002-9610(97)89592-X · DOI
  171. Borgen, 1997, Ann Surg Oncol, 4, 385, 10.1007/BF02305550 · DOI
  172. Carmalt, 1998, Aust N Z J Surg, 68, 712, 10.1111/j.1445-2197.1998.tb04657.x · DOI
  173. Vetto, 1999, Am J Surg, 177, 379, 10.1016/S0002-9610(99)00067-7 · DOI
  174. Herman, 2000, Does the prognosis differ compared to female? Neoplasma, 47, 191
  175. van Geel, 1985, Br J Surg, 72, 724, 10.1002/bjs.1800720918 · DOI
  176. Park, 2008, Yonsei Med J, 49, 978, 10.3349/ymj.2008.49.6.978 · DOI
  177. Botan, 2009, J Clin Oncol, 27, 10.1200/jco.2009.27.15_suppl.e11618 · DOI
  178. Andre, 2001, Acta Oncol, 40, 472, 10.1080/028418601750288190 · DOI
  179. Rudan, 1997, Acta Med Croatica, 51, 129
  180. Clark, 2000, Am Surg, 66, 502, 10.1177/000313480006600515 · DOI
  181. Giordano, 2005, Oncologist, 10, 471, 10.1634/theoncologist.10-7-471 · DOI
  182. Lanitis, 2008, World J Surg, 32, 2471, 10.1007/s00268-008-9713-7 · DOI
  183. Schaub, 2008, Am Surg, 74, 707, 10.1177/000313480807400807 · DOI
  184. Ashworth, 2008, J Clin Oncol, 26, 3785, 10.1200/JCO.2008.16.0812 · DOI

Metadata

Authors
Hayes, T. G.
Affiliations
United States Department of Veterans Affairs (US)
Corresponding author
Hayes, Teresa G
Venue
Expert Opinion on Pharmacotherapy
Publisher
Informa UK Limited
Published
2009-08-27
Volume
10
Issue
15
Pages
2499-2510
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
DOI
10.1517/14656560903200634
OpenAlex
W2037293746
Cited by
20
References
200
Citations by year
2022: 1 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 1 · 2013: 2
FWCI
2.01
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Male Breast Health Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
male breast cancer, tamoxifen, hormone therapy, aromatase inhibitors, androgen deprivation therapy, orchiectomy, BRCA2 mutation, oestrogen receptor, progesterone receptor, prognosis
MeSH terms
Age Factors, Androgens, Antineoplastic Agents, Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Male, Mutation, Neoplasm Staging, Prognosis, Breast Neoplasms, Male, BRCA2 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacologic treatment of male breast cancer. https://app.cochat.ai/papers/10.1517/14656560903200634
The paper
Hayes, T. G. (2009). Pharmacologic treatment of male breast cancer. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656560903200634

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.